Polynucleotides encoding optimized variants of anti-VEGF antibodies
US10906968B2 · kind B2 · utility
0Cited by
35References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2018 |
| Grant date | Feb 2, 2021 |
| Priority date | — |
| Expiry date | Aug 5, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.